Celgene’s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.
“It was not the breakthrough we were anticipating,” said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.The cost for this amazing advance in futile care? $6000-8000 per month. And there is already a drug on the market, folfirinox, that has demonstrated longer survival expectations that Abraxane. I'm sure